Juvenile myelomonocytic
leukemia is a rare disease that occurs mostly in the children who are under
four years of age. The abnormal growth of the monocytes results in the
accumulation of monocytes in the bone marrow.
This leads to improper
functioning of the bone marrow. The actual cause of juvenile myelomonocytic
leukemia is still unknown; however, mutation in the RAS gene is observed in
patients with the disease. Fatigue, weakness, dry cough, pallor, and fever are
major symptoms of the medical condition.
Get the detailed
analysis @ https://www.pharmaproff.com/report/juvenile-myelomonocytic-leukemia-therapeutics-pipeline-analysis
The University of
Minnesota is in the process of developing stem cell therapy for the treatment
of juvenile myelomonocytic leukemia. Celgene Corporation is also developing
azacytidine, a DNA methylation inhibitor, for the treatment of this medical
condition.
·
The report provides a
comprehensive understanding of the pipeline activities covering all drug
candidates under various stages of development, with the detailed analysis of
pipeline and clinical trials.
·
Pipeline analysis of
drugs by phases includes product description and development activities
including information about clinical results, designations, collaborations,
licensing, grants, technology, and others.
About Us:
Pharma Proff, is a
frontline market intelligence and consulting solutions provider catering to the
information and data needs of burgeoning sectors across the world, including
pharmaceutical and healthcare. With meticulously curated research reports on
the industry landscape, we empower companies in the healthcare and
pharmaceutical sectors to make informed business decisions and base their
marketing strategies with astuteness.
0 Comments